Welcome to our dedicated page for U S STEM CELL news (Ticker: USRM), a resource for investors and traders seeking the latest updates and insights on U S STEM CELL stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect U S STEM CELL's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of U S STEM CELL's position in the market.
U.S. Stem Cell, Inc. (OTC:USRM) announced a favorable ruling by California federal judge Jesus Bernal in a key case against Cell Surgical Network. The ruling stated that the defendants' Stromal Vascular Fraction (SVF) Surgical Procedure and Expanded Mesenchymal Stem Cells (MSC) Procedure are not classified as 'drugs' under the Federal Food, Drug, and Cosmetic Act, allowing the case to proceed to trial. This decision supports U.S. Stem Cell's stance that its treatments are medical procedures rather than drugs. The company plans to focus on its animal health division and regenerative medicine through VetBiologics.
U.S. Stem Cell (OTC PINK:USRM) has appointed Mark Borman as Chairman of the Board, succeeding Dr. William P. Murphy Jr, who transitions to Chairman Emeritus. Borman, with extensive experience in startups and multinational companies, aims to guide the company through its next phase, focusing on strategic growth and profitability. U.S. Stem Cell specializes in regenerative medicine and has trained over 700 professionals in stem cell therapies. The company plans to refocus on its animal health division while evaluating human health opportunities.
U.S. Stem Cell, Inc. (OTC PINK:USRM) is relaunching its Veterinary division, Vetbiologics, to innovate in the animal health sector. The U.S. pet market has seen continuous growth, reaching $99.1 billion in revenue last year, driven by pet ownership increases during the pandemic. The company plans to focus on aging pet requirements and wellness solutions. CEO Mike Tomas emphasized targeting consumer needs post-pandemic. Additionally, Vetbiologics will enhance its offerings alongside existing regenerative treatments to capitalize on industry trends.
U.S. Stem Cell (OTC: USRM) faced a setback as the 11th District Court upheld a ruling impacting its operations in regenerative medicine. The court affirmed that the company's surgical practices do not meet regulatory exceptions, leading to a halt in most product sales. Despite this, the company plans to explore legal options and refocus on growth, particularly in its animal health division. U.S. Stem Cell claims to have performed the most clinical treatments globally over the past 20 years and certified over 700 practitioners.
U.S. Stem Cell, Inc. (OTC PINK:USRM) announced a reinvestment effort led by NorthStar Biotech Group and USRM Board Members. This follows an ongoing legal challenge regarding the SVF Surgical Procedure, which the FDA has disputed. While the company maintains its position, the federal court has ruled against it, and an appeal is pending. Despite legal uncertainties, management expresses confidence in the company's technology and potential. Historically, U.S. Stem Cell has completed more treatments than any competitor, training over 700 physicians in autologous therapies globally.
U.S. Stem Cell, Inc. (OTC PINK:USRM) announced that oral arguments in the case USA v. U.S. Stem Cell Clinic are scheduled for January 11, 2021. This follows a challenge by the U.S. Department of Justice, alleging the company manufactured unapproved "stromal vascular fraction" products. A federal court previously ruled against U.S. Stem Cell, ordering the cessation of most product sales. CEO Mike Tomas expressed cautious optimism about the upcoming court date, viewing it as a chance to contest the summary judgment and present their case.
FAQ
What is the current stock price of U S STEM CELL (USRM)?
What is the market cap of U S STEM CELL (USRM)?
